Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News22 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News20 hours agoFranz Ferdinand: Australian Tour 2025
-
General21 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win
-
General14 hours agoDavid Littleproud’s own goal • Inside Story